Table 1: Phase II trials of IFN-α for metastatic melanoma.

Study referenceNo. of enrolled patients (followup)Therapy and IFN subspeciesDose—treatment arm (MU/m2)Schedule—treatment armORRCRPR

Ernstoff et al. 1983 [82]17α2b10–1005 d/week × 1 monthN/AN/A2

Creagan et al. 1984 [83]23α2a50Thrice weekly × 12 weeks2015

Creagan et al. 1985 [84]350α2a + cimetidine50Thrice weekly × 12 weeks2308

Creagan et al. 1984 [85]31α2a12Thrice weekly × 12 weeks2334

Legha et al. 1987 [86]62α2a1st arm—escalating (3–36 × 106 U/d)
2nd arm—fixed dose (18 × 106 U/d)
1st arm—daily during induction followed by thrice weekly
2nd arm—thrice weekly
1st—12.9%
2nd—16.1%
1st 0
2nd 0
1st—9.7%
2nd—6.5%

Hersey et al. 1985 [87]200α2a15–50Thrice weekly1020

Neefe et al. 1990 [88]97α2aEscalating: 3 to 36 × 106 UDaily for 10 days then 70 days total862

Dorval et al. 1986 [89]22α2b10Thrice weekly2424

Coates et al. 1986 [90]15α2a205 d/week every 2 weeks000